ERBB2 and neoplasm: In the other phase I/II study [113], patients with advanced HER2-amplified breast cancer received trastuzumab and suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule that is known to inhibit histone deacetylase and weaken signaling pathways which induce tumor progression and trastuzumab resistance.